[HTML] plos.org

[HTML][HTML] Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - PloS one, 2011 - journals.plos.org
Background Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods We completed a …
被引用次数：233 相关文章

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease.

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - Plos one, 2011 - europepmc.org
Background Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods We completed a …

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease

SL Dabora, DN Franz, S Ashwal… - PLoS …, 2011 - lomalinda.elsevierpure.com
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods: We completed a …

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF-D Levels Decrease.

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - PLoS …, 2011 - search.ebscohost.com
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods: We completed a …

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF-D Levels Decrease.

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - PLoS ONE, 2011 - go.gale.com
Background Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods We completed a …
[PDF] semanticscholar.org

[PDF][PDF] Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - 2011 - pdfs.semanticscholar.org
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods: We completed a …
[PDF] psu.edu

[PDF][PDF] Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - 2011 - Citeseer
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods: We completed a …
[HTML] nih.gov

[HTML][HTML] Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF-D Levels Decrease

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - PLoS ONE, 2011 - ncbi.nlm.nih.gov
Background Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods We completed a …
[PDF] researchgate.net

[PDF][PDF] Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - 2011 - researchgate.net
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods: We completed a …

[引用][C] Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF-D Levels Decrease

SL Dabora, DN Franz, S Ashwal, A Sagalowsky… - PLoS …, 2011 - ui.adsabs.harvard.edu
Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and
Other Tumors Regress and VEGF- D Levels Decrease - NASA/ADS Now on home page ads …